PKPeter Kaiser

Peter Kaiser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Kaiser has a total of 194 co-authors. Here are the top co-authors by number of shared publications:

  • Karin Flick

    Department of Biological Chemistry, School of Medicine, Center for Epigenetics and Metabolism, Chao Family Comprehensive Cancer Center, University of California, Irvine, 240D Med Sci I, Irvine, California 92697-1700, United States

    15 shared publications
  • Lan Huang

    Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA 92697, USA; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA

    9 shared publications
  • Da-Wei Lin

    Department of Biological Chemistry, School of Medicine, University of California, Irvine, USA

    7 shared publications
  • Linda Lauinger

    Department of Biological Chemistry University of California, Irvine Irvine California USA

    6 shared publications
  • Ikram Ouni

    University of California Irvine Department of Biological Chemistry, College of Medicine 240D Med Sci I Irvine, CA 92697-1700, USA

    5 shared publications
  • Radhika Mathur

    Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697-1700

    5 shared publications

Latest Publications

  • Open Access

    Carboxy-Methylation of the Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Integrates Methionine Availability with Methionine Addicted Cancer Cell Proliferation

    by Anna Andronicos, Kiku C. Yoneda, Da-Wei Lin, Fiona V. Law, Hosung Bae, Ali Basirattalab, Nicholas A. Graham, Cholsoon Jang, Peter Kaiser

    Cancer cells exhibit a well-documented, yet poorly understood, dependence on exogenous methionine, despite retaining the capacity to convert homocysteine to methionine. In contrast, non-tumorigenic cells can proliferate when methionine is replaced by homocysteine. To investigate the mechanistic basis of this methionine dependence, we examined how methionine metabolism impacts cancer cell proliferation. We identified carboxy-methylation of the catalytic subunit of Protein Phosphatase 2A (PP2A) as a critical node linking methionine availability to proliferation. PP2A methylation was found to be highly sensitive to intracellular S-adenosylmethionine (SAM) levels, with reduced methylation correlating with impaired proliferation under methionine restriction. Overexpression of Protein Phosphatase Methylesterase-1 (PME-1), which demethylates PP2A, or expression of a Leu309-deleted PP2A mutant that mimics the demethylated form, was sufficient to reduce proliferation even in methionine-independent cells. These findings support a model in which methionine limitation lowers SAM availability, thereby decreasing PP2A methylation and impairing cell proliferation. Our study reveals a mechanistic link between methionine metabolism and cell proliferation and suggests that PP2A methylation plays a key role in the unique methionine dependence of cancer cells.


  • Open Access

    Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A

    by Vaishali Jayashankar, Peter Kubiniok, Alison N McCracken, Rebeca G Gentry, Kazumi H Eckenstein, Lorenzo Sernissi, Vito Vece, Jean-Baptiste Garsi, Sarah Y Valles, Sunhee Jung, et al.

    Sphingosine and constrained analogs like FTY720 and SH-BC-893 restrain tumor growth through incompletely defined mechanisms that include protein phosphatase 2A (PP2A) activation. Here we show that these compounds directly bind not only the PP2A scaffolding subunit PPP2R1A, but also the structurally related karyopherins importin-β1 (KPNB1), transportin-1 (TNPO1), importin-5 (IPO5), and importin-7 (IPO7). Binding to sphingosine-like molecules triggers reversible unfolding of these target proteins, resulting in activation of PP2A and inhibition of importins. Although sphingosine engages these proteins, ceramide does not, suggesting that these two endogenous tumor-suppressive sphingolipids work through distinct mechanisms. Simultaneous PP2A activation and importin inhibition reduces nuclear levels of proteins that drive cancer progression and therapeutic resistance such as JUN, YAP, MYC, androgen receptor, hnRNPA1, and NF-κB under conditions where compounds that target PP2A or KPNB1 individually are inactive. These findings provide new insights into sphingolipid biology and highlight a possible path toward cancer therapeutics that could overcome drug resistance.


  • Distinct Stress Regulators in the CRL Family: Emerging Roles of F‐Box Proteins

    by Jiwon Hwang, Linda Lauinger, Peter Kaiser

    Cullin‐RING ligases (CRLs) are central regulators of environmental and cellular stress responses, orchestrating diverse processes through the ubiquitination of substrate proteins. As modular complexes, CRLs employ substrate‐specific adaptors to target proteins for degradation and other ubiquitin‐mediated processes, enabling dynamic adaptation to environmental cues. Recent advances have highlighted the largest CRL subfamily SCF (Skp1‐cullin‐F‐box) in environmental sensing, a role historically underappreciated for SCF ubiquitin ligases. Notably, emerging evidence suggests that the F‐box domain, a 50‐amino acid motif traditionally recognized for mediating protein‐protein interactions, can act as a direct environmental sensor due to its ability to bind heavy metals. Despite these advances, the roles of many CRL components in environmental sensing remain poorly understood. This review provides an overview of CRLs in stress response regulation and emphasizes the emerging functions of F‐box proteins in environmental adaptation.


  • Open Access

    Nutrient control of splice site selection contributes to methionine addiction of cancer

    by Da-Wei Lin, Francisco G. Carranza, Stacey Borrego, Linda Lauinger, Lucas Dantas de Paula, Harika R. Pulipelli, Anna Andronicos, Klemens J. Hertel, Peter Kaiser


  • Open Access

    Pyrimidine Triones as Potential Activators of p53 Mutants

    by Maryam M. Jebril Fallatah, Özlem Demir, Fiona Law, Linda Lauinger, Roberta Baronio, Linda Hall, Elodie Bournique, Ambuj Srivastava, Landon Tyler Metzen, Zane Norman, et al.

    P53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.


  • Open Access

    Cadmium binding by the F-box domain induces p97-mediated SCF complex disassembly to activate stress response programs

    by Linda Lauinger, Anna Andronicos, Karin Flick, Clinton Yu, Geetha Durairaj, Lan Huang, Peter Kaiser

    The F-box domain is a highly conserved structural motif that defines the largest class of ubiquitin ligases, Skp1/Cullin1/F-box protein (SCF) complexes. The only known function of the F-box motif is to form the protein interaction surface with Skp1. Here we show that the F-box domain can function as an environmental sensor. We demonstrate that the F-box domain of Met30 is a cadmium sensor that blocks the activity of the SCFMet30 ubiquitin ligase during cadmium stress. Several highly conserved cysteine residues within the Met30 F-box contribute to binding of cadmium with a KD of 8 µM. Binding induces a conformational change that allows for Met30 autoubiquitylation, which in turn leads to recruitment of the segregase Cdc48/p97/VCP followed by active SCFMet30 disassembly. The resulting inactivation of SCFMet30 protects cells from cadmium stress. Our results show that F-box domains participate in regulation of SCF ligases beyond formation of the Skp1 binding interface.


  • Small-molecule correctors and stabilizers to target p53

    by Maryam M.J. Fallatah, Fiona V. Law, Warren A. Chow, Peter Kaiser


    • 1 January 2023
      • Vol. 13  (12) , 6011-6025

    Original Induction of resistance to oxaliplatin in cancer by a microRNA/Fem1B/Gli1 pathway

    by Yi-Chen Su, Landon Tyler Metzen, Leandro Martin Velez, Elodie Bournique, Marcus Seldin, Remi Buisson, Wei-Wen Kuo, Chih-Yang Huang, Peter Kaiser

    Colorectal cancer is among the most common cancers worldwide and a frequent cause of cancer related deaths. Oxaliplatin is the first line chemotherapeutics for treatment, but the development of resistance leads to recurrence of oxaliplatin insensitive tumors. To understand possible mechanisms of drug tolerance we developed oxaliplatin resistant derivatives (OR-LoVo) of the established LoVo cell line originally isolated from a metastatic colon adenocarcinoma. We compared the microRNA (miRNA) expression profile of the cell pair and found expression of miR-29a-3p significantly increased in OR-LoVo cells compared to parent cells. In addition, miR-29a-3p was significantly elevated in tumor tissue when compared to matched surrounding tissue in human, suggesting potential clinical importance. Ectopic miR-29-a-3p expression induced chemoresistance in a number of different cancer cell lines as well as colorectal tumors in mice. We further demonstrated that miR-29-a-3p downregulates expression of the ubiquitin ligase component FEM1B and that reduction of Fem1b levels is sufficient to confer oxaliplatin resistance. FEM1B targets the glioma associated oncogene Gli1 for degradation, suggesting that increased Gli1 levels could contribute to oxaliplatin tolerance. Accordingly, knockdown of GLI1 reverted chemoresistance of OR-LoVo cells. Mechanistically, resistant cells experienced significantly lower DNA damage upon oxaliplatin treatment, which can be partially explained by reduced oxaliplatin uptake and enhanced repair. These results suggest that miR-29a-3p overexpression induces oxaliplatin resistance through misregulation of Fem1B and Gli1 levels. TCGA analyses provides strong evidence that the reported findings regarding induced drug tolerance by the miR-29a/Fem1B axis is clinically relevant. The reported findings can help to predict oxaliplatin sensitivity and resistance of colorectal tumors.


  • Discovery of compounds that reactivate p53 mutants in vitro and in vivo

    by Geetha Durairaj, Özlem Demir, Bryant Lim, Roberta Baronio, Delia Tifrea, Linda V. Hall, Jacob C. DeForest, Linda Lauinger, Maryam M. Jebril Fallatah, Clinton Yu, et al.